Download MendeleyAffimer-mediated locking of p21-activated kinase 5 in an intermediate activation state results in kinase inhibition.
Martin, H.L., Turner, A.L., Higgins, J., Tang, A.A., Tiede, C., Taylor, T., Siripanthong, S., Adams, T.L., Manfield, I.W., Bell, S.M., Morrison, E.E., Bond, J., Trinh, C.H., Hurst, C.D., Knowles, M.A., Bayliss, R.W., Tomlinson, D.C.(2023) Cell Rep 42: 113184-113184
- PubMed: 37776520 Search on PubMed
- DOI: https://doi.org/10.1016/j.celrep.2023.113184
- Primary Citation Related Structures:
8C12 - PubMed Abstract:
Kinases are important therapeutic targets, and their inhibitors are classified according to their mechanism of action, which range from blocking ATP binding to covalent inhibition. Here, a mechanism of inhibition is highlighted by capturing p21-activated kinase 5 (PAK5) in an intermediate state of activation using an Affimer reagent that binds in the P+1 pocket. PAK5 was identified from a non-hypothesis-driven high-content imaging RNAi screen in urothelial cancer cells. Silencing of PAK5 resulted in reduced cell number, G1/S arrest, and enlargement of cells, suggesting it to be important in urothelial cancer cell line survival and proliferation. Affimer reagents were isolated to identify mechanisms of inhibition. The Affimer PAK5-Af17 recapitulated the phenotype seen with siRNA. Co-crystallization revealed that PAK5-Af17 bound in the P+1 pocket of PAK5, locking the kinase into a partial activation state. This mechanism of inhibition indicates that another class of kinase inhibitors is possible.
- BioScreening Technology Group, Leeds Institutes of Molecular Medicine, University of Leeds, Leeds LS9 7TF, UK; Division of Molecular Medicine, Leeds Institute of Medical Research at St James's University Hospital, University of Leeds, Leeds LS9 7TF, UK; School of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, UK.
Organizational Affiliation:
